title: Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
abstract: In the era of highly effective direct acting antiviral (DAA) drugs for the treatment of chronic hepatitis C (CHC) infection, where eradication is almost ensured with minimal side effects, all hepatitis C carriers should benefit theoretically. In the real world setting however, only a small proportion will benefit at this time point due to the multiple barriers to accessing therapy. Given that universal treatment is unlikely, treatment with DAAs will likely be restricted to those with the highest health benefits, and for those who can afford the high expense of a treatment course. Those with the highest unmet needs include those who have failed previous interferon-based therapy or who are interferon-ineligible with evidence of active disease, those with advance liver disease, and those with recurrence of hepatitis C after liver transplantation. In the future, the focus should be on increasing access to treatment for those infected with CHC.
authors.affiliation: James Fung, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong, China.
authors.forename: James
authors.initials: J
authors.lastname: Fung
keywords: Benefit; Chronic hepatitis C; Cirrhosis; Direct acting antivirals; Liver transplantation; Treatment; Unmet needs